SENSOCURE AS

Their core work

SENSOCURE AS is a Norwegian medical device SME developing biosensor technology for the continuous, real-time detection of ischemia — the dangerous condition where blood flow to tissue is interrupted. Their core technology uses conductometric micro-sensors (measuring tissue pCO2) to alert surgeons before ischemic tissue damage becomes irreversible. Their primary application is intraoperative and post-operative monitoring in replantation, reconstructive/plastic surgery, and orthopedic procedures, where early ischemia detection can mean the difference between saving and losing a limb or flap. They progressed from clinical feasibility validation in 2015 to full product development by 2021, suggesting a company on the path from prototype to market-ready diagnostic device.

What they specialise in

How they've shifted over time

SENSOCURE's H2020 trajectory follows a disciplined single-technology development arc. Their 2015 SME Phase 1 project (CLINISC) was a pure feasibility study — clinical validation of the core pCO2 sensor concept with no elaborated keyword profile, suggesting they were still proving the basic principle. By 2021, with IscAlert, the keyword set expands significantly to cover specific surgical disciplines (replantation, orthopedic surgery, reconstructive surgery), sensor modalities (bio-sensor, micro-sensor, conductometric), and clinical framing (diagnostic devices) — indicating the technology matured from a concept into a defined product targeting specific surgical workflows. There is no pivot or diversification: the entire arc is one company deepening its expertise in a single high-value clinical problem.

SENSOCURE is on a commercialization trajectory — having completed Phase 2 SME Instrument funding through 2023, they are likely in or approaching market entry for their IscAlert surgical monitoring device.

How they like to work

SENSOCURE has operated exclusively as a solo project coordinator under the SME Instrument scheme, which is specifically designed for single-company development — so the absence of consortium partners reflects the funding mechanism rather than a preference for isolation. Their consistent coordinator role across both projects signals a company that drives its own agenda rather than joining others' initiatives. For future collaborations, they would likely enter as a technology provider or clinical validation partner rather than a consortium follower.

SENSOCURE has no recorded consortium partners in H2020, consistent with their exclusive use of the SME Instrument (a solo-company funding scheme). Their external network, if any, would be through clinical trial hospitals and surgical departments rather than R&D partners visible in CORDIS data.

What sets them apart

SENSOCURE occupies a narrow but high-value niche: continuous intraoperative ischemia monitoring using conductometric micro-sensors — a space with few dedicated commercial players. Their technology addresses a real clinical gap, as current ischemia monitoring in surgical settings is largely intermittent or observer-dependent. A consortium builder in medical devices, digital health, or surgical robotics would find them valuable as the sensing/diagnostic component in a larger platform, or as a clinical validation partner for tissue perfusion monitoring.

Highlights from their portfolio

• IscAlert
  The largest funded project (€1.96M, SME Phase 2) represents the full commercial development push for a real-time biosensor system targeting ischemia in multiple surgical specialties — a rare combination of life-critical application and proprietary conductometric sensing technology.
• CLINISC
  The Phase 1 seed project that clinically validated the pCO2 sensor concept in 2015, establishing the evidence base that enabled the much larger IscAlert funding six years later.